A Systematic Review of Health Economic Evaluations of Diagnostic Biomarkers

Applied Health Economics and Health Policy

Volumn 14, Issue 1, 2016, Pages 51-65

  Oosterhoff, Marije ^a   van der Maas, Marloes E ^a   Steuten, Lotte M G ^a,b  

^a PANAXEA B V   (Netherlands)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; K RAS PROTEIN;

CANCER DIAGNOSIS; CARDIOVASCULAR DISEASE; COLORECTAL CANCER; COST; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DIAGNOSTIC ACCURACY; ECONOMIC EVALUATION; FAMILIAL DISEASE; GENETIC SCREENING; GROSS NATIONAL PRODUCT; HEALTH ECONOMICS; HUMAN; METHODOLOGY; PATIENT PREFERENCE; PERSONALIZED MEDICINE; POPULATION DENSITY; QUALITY ADJUSTED LIFE YEAR; RESPIRATORY TRACT DISEASE; REVIEW; SYSTEMATIC REVIEW; THYROID CANCER;

BIOMARKERS; COST-BENEFIT ANALYSIS; HUMANS;

EID: 84958116378     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-015-0198-x     Document Type: Review

References (59)

1. Hagen TJ. Recent trends in biomarker research and development. Biochem Anal Biochem. 2012;1:e108.
2. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95.
3. Pham B, Tu HA, Han D, Pechlivanoglou P, Miller F, Rac V, et al. Early economic evaluation of emerging health technologies: protocol of a systematic review. Syst Rev. 2014;3:81.
4. Schneider J, Sidhu M, Doucet C, Ohsfeldt R, Chalfin D. Economics of cancer. Pers Med. 2012;9(8):829–37.
5. Nordstrom A, Lewensohn R. Metabolomics: moving to the clinic. J Neuroimmune Pharmacol Off J Soc Neuroimmune Pharmacol. 2010;5(1):4–17.
6. Wong WB, Carlson JJ, Thariani R, Veenstra DL. Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics. 2010;28(11):1001–13.
7. Caffrey M. When science outpaces payers: reimbursement in molecular diagnostics. AJMC. 2014;20(7):1–3.
8. Cohen JP. Overcoming regulatory and economic challenges facing pharmacogenomics. New Biotechnol. 2012;29(6):751–6.
9. Cohen J, Wilson A, Manzolillo K. Clinical and economic challenges facing pharmaeconomics. Pharmacogenomics J. 2013;13(4):378–88.
10. Gazelle GS, Kessler L, Lee DW, McGinn T, Menzin J, Neumann PJ, et al. A framework for assessing the value of diagnostic imaging in the era of comparative effectiveness research. Radiology. 2011;261(3):692–8.
11. Peabody JW, Shimkhada R, Tong KB, Zubiller MB. New thinking on clinical utility: hard lessons for molecular diagnostics. Am J Manag Care. 2014;20(9):750–6.
12. Gazelle GS, McMahon PM, Siebert U, Beinfeld MT. Cost-effectiveness analysis in the assessment of diagnostic imaging technologies. Radiology. 2005;235(2):361–70.
13. European Network for Health Technology Assessment. HTA core model for diagnostic technologies v1.0r. 2008. http://www.eunethta.eu/outputs/hta-core-model-diagnostic-technologies-10r. Accessed 28 Aug 2015.
14. Alton V, Eckerlund I, Norlund A. Health economic evaluations: how to find them. Int J Technol Assess Health Care. 2006;22(4):512–7.
15. Glanville J, Fleetwood K, Yellowlees A, Kaunelis D, Mensinkai S. Development and testing of search filters to identify economic evaluations in MEDLINE and EMBASE. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2009.
16. World Health Organization (WHO). Global status report on noncommunicable diseases 2010: description of the global burden of NCDs, their risk factors and determinants. April 2011. http://www.who.int/nmh/publications/ncd_report2010/en/. Accessed 28 Aug 2015.
17. Country and lending groups 2015. http://data.worldbank.org. Accessed 28 Aug 2015.
18. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMC Med. 2013;11:80.
19. Husereau D, Marshall DA, Levy AR, Peacock S, Hoch JS. Health technology assessment and personalized medicine: are economic evaluation guidelines sufficient to support decision making? Int J Technol Assess Health Care. 2014;30(2):179–87.
20. Breijer MC, van Doorn HC, Clark TJ, Khan KS, Timmermans A, Mol BW, et al. Diagnostic strategies for endometrial cancer in women with postmenopausal bleeding: cost-effectiveness of individualized strategies. Eur J Obstet Gynecol Reprod Biol. 2012;163(1):91–6.
21. Bruno P, Ricci A, Esposito MC, Scozzi D, Tabbi L, Sposato B, et al. Efficacy and cost effectiveness of rapid on site examination (ROSE) in management of patients with mediastinal lymphadenopathies. Eur Rev Med Pharmacol Sci. 2013;17(11):1517–22.
22. Collinson PO, Gaze DC, Thokala P, Goodacre S. Randomised assessment of treatment using panel assay of cardiac markers—contemporary biomarker evaluation (RATPAC CBE). Health Technol Assess (Winch, Engl). 2013;17(15):v–vi 1–122.
23. Fitzgerald P, Goodacre SW, Cross E, Dixon S. Cost-effectiveness of point-of-care biomarker assessment for suspected myocardial infarction: the Randomized Assessment of Treatment using Panel Assay of Cardiac markers (RATPAC) trial. Acad Emerg Med. 2011;18(5):488–95.
24. Gani MS, Shafee AM, Soliman IY. Ultrasound guided percutaneous fine needle aspiration biopsy/automated needle core biopsy of abdominal lesions: effect on management and cost effectiveness. Ann Afr Med. 2011;10(2):133–8.
25. Gausachs M, Mur P, Corral J, Pineda M, Gonzalez S, Benito L, et al. MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study. Eur J Hum Genet EJHG. 2012;20(7):762–8.
26. Heilbrun ME, Yu J, Smith KJ, Dechet CB, Zagoria RJ, Roberts MS. The cost-effectiveness of immediate treatment, percutaneous biopsy and active surveillance for the diagnosis of the small solid renal mass: evidence from a Markov model. J Urol. 2012;187(1):39–43.
27. Heller M, Zanocco K, Zydowicz S, Elaraj D, Nayar R, Sturgeon C. Cost-effectiveness analysis of repeat fine-needle aspiration for thyroid biopsies read as atypia of undetermined significance. Surgery. 2012;152(3):423–30.
28. Kwon JS, Gutierrez-Barrera AM, Young D, Sun CC, Daniels MS, Lu KH, et al. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(27):4214–20.
29. Kwon JS, Scott JL, Gilks CB, Daniels MS, Sun CC, Lu KH. Testing women with endometrial cancer to detect Lynch syndrome. J Clin Oncol. 2011;29(16):2247–52.
30. Fernandez VL, Rial MB, Represas CR, Pineiro AG, Del Campo Perez V, Fernandez-Villar A. Cost-effectiveness analysis of transbronchial needle aspiration of pulmonary lesions without endobronchial affectation. Arch Bronconeumol. 2012;48(12):448–52.
31. Shaw AD, Chalfin DB, Kleintjens J. The economic impact and cost-effectiveness of urinary neutrophil gelatinase-associated lipocalin after cardiac surgery. Clin Ther. 2011;33(11):1713–25.
32. Steinfort DP, Liew D, Irving LB. Radial probe EBUS versus CT-guided needle biopsy for evaluation of peripheral pulmonary lesions: an economic analysis. Eur Respir J. 2013;41(3):539–47.
33. Vanni T, Legood R, Franco EL, Villa LL. Mendes Luz P, Schwartsmann G. Economic evaluation of strategies for managing women with equivocal cytological results in Brazil. Int J Cancer. 2011;129(3):671–9.
34. Yip L, Farris C, Kabaker AS, Hodak SP, Nikiforova MN, McCoy KL, et al. Cost impact of molecular testing for indeterminate thyroid nodule fine-needle aspiration biopsies. J Clin Endocrinol Metab. 2012;97(6):1905–12.
35. Zanocco K, Heller M, Elaraj D, Sturgeon C. Cost effectiveness of intraoperative pathology examination during diagnostic hemithyroidectomy for unilateral follicular thyroid neoplasms. J Am Coll Surg. 2013;217(4):702–10.
36. Naval JC, Alonso JLI, Carrasco JG, Hernandez IS, Sanchez CA, Frances JF, et al. Clinical utility and economic impact of conventional transbronchial needle aspiration of mediastinal lymphadenopathies in bronchogenic carcinoma. Archiv Bronconeumol. 2013;49(2):41–6.
37. Covarelli P, Badolato M, Tomassini GM, Poponesi V, Listorti C, Castellani E, et al. Sentinel lymph node biopsy under local anaesthesia versus general anaesthesia: reliability and cost-effectiveness analysis in 153 patients with malignant melanoma. In Vivo. 2012;26(2):315–8.
38. Li H, Robinson KA, Anton B, Saldanha IJ, Ladenson PW. Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab. 2011;96(11):E1719–26.
39. Verry H, Lord SJ, Martin A, Gill G, Lee CK, Howard K, et al. Effectiveness and cost-effectiveness of sentinel lymph node biopsy compared with axillary node dissection in patients with early-stage breast cancer: a decision model analysis. Br J Cancer. 2012;106(6):1045–52.
40. Behl AS, Goddard KA, Flottemesch TJ, Veenstra D, Meenan RT, Lin JS, et al. Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer. J Natl Cancer Inst. 2012;104(23):1785–95.
41. Lala A, Berger JS, Sharma G, Hochman JS, Scott Braithwaite R, Ladapo JA. Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis. J Thromb Haemost. 2013;11(1):81–91.
42. Oppong R, Jit M, Smith RD, Butler CC, Melbye H, Molstad S, et al. Cost-effectiveness of point-of-care C-reactive protein testing to inform antibiotic prescribing decisions. Br J Gen Pract J R Coll Gen Pract. 2013;63(612):e465–71.
43. Panattoni L, Brown PM, Ao BT, Webster M, Gladding P. The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation. PharmacoEconomics. 2012;30(11):1067–84.
44. Retel VP, Joore MA, Linn SC, Rutgers EJ, van Harten WH. Scenario drafting to anticipate future developments in technology assessment. BMC Res Notes. 2012;5:442.
45. Romanus D, Cardarella S, Cutler D, Landrum MB, Lindeman NI, Gazelle GS. Cost-effectiveness of multiplexed predictive biomarker screening in non-small cell lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2015.
46. Shiroiwa T, Motoo Y, Tsutani K. Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer. Mol Diagn Ther. 2010;14(6):375–84.
47. Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, Boland CR, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med. 2011;155(2):69–79.
48. Mvundura M, Grosse SD, Hampel H, Palomaki GE. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med. 2010;12(2):93–104.
49. Nherera L, Marks D, Minhas R, Thorogood M, Humphries SE. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart. 2011;97(14):1175–81.
50. Perez MV, Kumarasamy NA, Owens DK, Wang PJ, Hlatky MA. Cost-effectiveness of genetic testing in family members of patients with long-QT syndrome. Circ Cardiovasc Qual Outcomes. 2011;4(1):76–84.
51. Sharma P, Boyers D, Boachie C, Stewart F, Miedzybrodzka Z, Simpson W, et al. Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation. Health technol Assess (Winch, Engl). 2012;16(17):1–266.
52. Wordsworth S, Leal J, Blair E, Legood R, Thomson K, Seller A, et al. DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model. Eur Heart J. 2010;31(8):926–35.
53. Frank M, Mittendorf T. Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness: a systematic review. Pharmacoeconomics. 2013;31(3):215–28.
54. Annemans L, Redekop K, Payne K. Current methodological issues in the economic assessment of personalized medicine. Value Health J Int Soc Pharmacoecon Outcomes Res. 2013;16(6 Suppl):S20–6.
55. Payne K, Annemans L. Reflections on market access for personalized medicine: recommendations for Europe. Value Health J Int Soc Pharmacoecon Outcomes Res. 2013;16(6 Suppl):S32–8.
56. Towse A, Garrison LP Jr. Economic incentives for evidence generation: promoting an efficient path to personalized medicine. Value Health J Int Soc Pharmacoecon Outcomes Res. 2013;16(6 Suppl):S39–43.
57. Buchanan J, Wordsworth S, Schuh A. Issues surrounding the health economic evaluation of genomic technologies. Pharmacogenomics. 2013;14(15):1833–47.
58. Veenstra DL, Brooks PJ. The cost-effectiveness of clinical sequencing. Discussion Paper. Washington, DC: Institute of Medicine; 2015.
59. Bhatt AN, Mathur R, Farooque A, Verma A, Dwarakanath BS. Cancer biomarkers—current perspectives. Indian J Med Res. 2010;132:129–49.